Amakem (Belgium) a development-stage pharmaceutical company focused on glaucoma and other ophthalmic indications, closed a $25.3M Series A financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Vesalius BioCapital and Life Sciences Research Partners.